3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
16
Urogenital Neoplasms
2
Urinary Bladder Neoplasms
2
Urothelial Cancer
1
Urologic Neoplasms
1
Urologic Diseases
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Radiation Injuries
1
Prostate Adenocarcinoma
1
Neoplasms by Site
1
Neoplasms
1
Melanoma
1
Male Urogenital Diseases
1
Lymphatic Metastasis
1
Infiltrating Bladder Urothelial Carcinoma
1
Genital Neoplasms, Male
1
Female Urogenital Diseases
1
Encopresis
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
padeliporfin
5
Mitomycin
3
pembrolizumab
2
alectinib
2
Standard of Care
2
Pluvicto
2
Nivolumab
2
Cisplatin
2
Abiraterone Acetate
2
valrubicin
1
relatlimab
1
palladium-bacteriopheophorbide
1
palbociclib
1
osimertinib
1
onapristone
1
olaparib
1
gallium 68 PSMA-11
1
enzalutamide
1
enfortumab vedotin
1
darolutamide
1
cobimetinib
1
apalutamide
1
abiraterone
1
Therapeutics
1
Taxes
1
Sunitinib
1
Radiation Dose Hypofractionation
1
Pemetrexed
1
Paclitaxel
1
Ipilimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
Radiation Dose Hypofractionation
×
Genitourinary
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled